RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.